Extended Data Fig. 4: Changes in free fatty acids and lipid parameters in humans with multiple ascending doses of AMG 133. | Nature Metabolism

Extended Data Fig. 4: Changes in free fatty acids and lipid parameters in humans with multiple ascending doses of AMG 133.

From: A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Extended Data Fig. 4

(a–d) Mean (SE) change from baseline in fasting free fatty acids, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (A), fasting triglycerides, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (B), fasting total cholesterol, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (C), fasting LDL, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (D) after multiple ascending doses of AMG 133 or placebo. Arrows indicate when the investigational product was administrated: at day 1, 29, and 57.

Source data

Back to article page